CERo Net Working Capital from 2010 to 2024

CEROW Stock   0.01  0.01  30.35%   
CERo Therapeutics Net Working Capital yearly trend continues to be fairly stable with very little volatility. Net Working Capital is likely to outpace its year average in 2024. During the period from 2010 to 2024, CERo Therapeutics Net Working Capital regression line of quarterly data had mean square error of 12.3 T and geometric mean of  14,552,330. View All Fundamentals
 
Net Working Capital  
First Reported
2010-12-31
Previous Quarter
5.3 M
Current Value
9.4 M
Quarterly Volatility
4.5 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check CERo Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CERo Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 121.5 K, Interest Income of 121.5 K or Depreciation And Amortization of 994.6 K, as well as many indicators such as . CERo financial statements analysis is a perfect complement when working with CERo Therapeutics Valuation or Volatility modules.
  
Check out the analysis of CERo Therapeutics Correlation against competitors.

Latest CERo Therapeutics' Net Working Capital Growth Pattern

Below is the plot of the Net Working Capital of CERo Therapeutics Holdings over the last few years. It is CERo Therapeutics' Net Working Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in CERo Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Net Working Capital10 Years Trend
Slightly volatile
   Net Working Capital   
       Timeline  

CERo Net Working Capital Regression Statistics

Arithmetic Mean15,526,349
Geometric Mean14,552,330
Coefficient Of Variation29.29
Mean Deviation3,454,290
Median17,685,280
Standard Deviation4,547,956
Sample Variance20.7T
Range12.4M
R-Value(0.67)
Mean Square Error12.3T
R-Squared0.45
Significance0.01
Slope(681,346)
Total Sum of Squares289.6T

CERo Net Working Capital History

20249.4 M
20235.3 M
20225.9 M

About CERo Therapeutics Financial Statements

CERo Therapeutics investors use historical fundamental indicators, such as CERo Therapeutics' Net Working Capital, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in CERo Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Working Capital5.3 M9.4 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for CERo Stock Analysis

When running CERo Therapeutics' price analysis, check to measure CERo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CERo Therapeutics is operating at the current time. Most of CERo Therapeutics' value examination focuses on studying past and present price action to predict the probability of CERo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CERo Therapeutics' price. Additionally, you may evaluate how the addition of CERo Therapeutics to your portfolios can decrease your overall portfolio volatility.